Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?
暂无分享,去创建一个
[1] I. Slutsky,et al. Amyloid-β as a positive endogenous regulator of release probability at hippocampal synapses , 2009, Nature Neuroscience.
[2] M. Gold,et al. SB‐742457 and donepezil in Alzheimer disease: a randomized, placebo‐controlled study , 2011, International journal of geriatric psychiatry.
[3] N. Jahanshad,et al. Common Alzheimer's Disease Risk Variant Within the CLU Gene Affects White Matter Microstructure in Young Adults , 2011, The Journal of Neuroscience.
[4] Neuropathology of Alzheimer's Disease , 2014 .
[5] George Perry,et al. Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. , 2010, Biochimica et biophysica acta.
[6] Xin Wu,et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.
[7] M. Pelto-huikko,et al. The expression of ornithine decarboxylase antizyme mRNA and protein in rat motoneurons , 1995, Neuroscience Letters.
[8] R. Mahley,et al. Alzheimer disease: Multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches , 2009, Annals of neurology.
[9] John Hardy,et al. The spread of neurodegenerative disease. , 2012, The New England journal of medicine.
[10] S. Stahl. Cholinesterase inhibitors for Alzheimer's disease. , 1998, Hospital practice.
[11] U. Müller,et al. The physiological functions of the β-amyloid precursor protein APP , 2012, Experimental Brain Research.
[12] K. Blennow,et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.
[13] H. Loetscher,et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. , 2012, Journal of Alzheimer's disease : JAD.
[14] D. Holtzman,et al. Alzheimer disease in 2020. , 2012, Cold Spring Harbor perspectives in medicine.
[15] B. Doble,et al. Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. , 2008, The Journal of clinical investigation.
[16] M. Leissring,et al. Proteolytic degradation of amyloid β-protein. , 2012, Cold Spring Harbor perspectives in medicine.
[17] Eric B Larson,et al. Late-life dementias: does this unyielding global challenge require a broader view? , 2009, JAMA.
[18] S. de Santi,et al. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. , 2010, Journal of Alzheimer's disease : JAD.
[19] Katharina Buerger,et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. , 2002, Archives of neurology.
[20] M. Billingsley,et al. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. , 1997, The Biochemical journal.
[21] P. Scheltens,et al. Amyloid β 38, 40, and 42 species in cerebrospinal fluid: More of the same? , 2005 .
[22] J. Morris,et al. Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.
[23] B. Allinquant. Faculty Opinions recommendation of A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. , 2008 .
[24] D. Saumier,et al. Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer’s disease: ADAS-cog subscale results from the Alphase study , 2009, The journal of nutrition, health & aging.
[25] D. Selkoe,et al. A Critical Function for β-Amyloid Precursor Protein in Neuronal Migration Revealed by In Utero RNA Interference , 2007, The Journal of Neuroscience.
[26] John Hardy,et al. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal , 2009, Journal of neurochemistry.
[27] J. Kornhuber,et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease , 1997, Neuroscience Letters.
[28] Brad J Kolls,et al. A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE , 2010, Neurology.
[29] P. Maher,et al. Metabolic links between diabetes and Alzheimer’s disease , 2009, Expert review of neurotherapeutics.
[30] Malorye Allison,et al. NCATS launches drug repurposing program , 2012, Nature Biotechnology.
[31] D. Blacker,et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.
[32] P. Davies,et al. Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models , 2011, The Journal of Biological Chemistry.
[33] Thomas W. Mühleisen,et al. The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.
[34] Robert C Green,et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. , 2009, JAMA.
[35] J. Trojanowski,et al. CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease , 2010, Neurology.
[36] L. Mucke,et al. Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks , 2010, Nature Neuroscience.
[37] P. Lewczuk,et al. CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia , 2006, Brain : a journal of neurology.
[38] S. Potkin,et al. Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort , 2010, Neurology.
[39] B. Maher. ENCODE: The human encyclopaedia , 2012, Nature.
[40] Hendrik van den Bussche,et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials , 2005, BMJ : British Medical Journal.
[41] R. Mahley,et al. Apolipoprotein E4 Domain Interaction Mediates Detrimental Effects on Mitochondria and Is a Potential Therapeutic Target for Alzheimer Disease* , 2010, The Journal of Biological Chemistry.
[42] Bryce Vissel,et al. The roles of TNF in brain dysfunction and disease. , 2010, Pharmacology & therapeutics.
[43] P. Williams,et al. Natural products as a source of Alzheimer's drug leads. , 2011, Natural product reports.
[44] W. M. van der Flier,et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.
[45] M. Pangalos,et al. Treatment strategies targeting amyloid β-protein. , 2012, Cold Spring Harbor perspectives in medicine.
[46] K. Wark,et al. Engineered antibody approaches for Alzheimer's disease immunotherapy. , 2012, Archives of biochemistry and biophysics.
[47] T. Kuo,et al. Burden of Alzheimer's Disease–Related Mortality in the United States, 1999–2008 , 2012, Journal of the American Geriatrics Society.
[48] L. Doncarlos,et al. Neuroprotection by estradiol , 2001, Progress in Neurobiology.
[49] B. Strooper,et al. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.
[50] F. Mascarelli,et al. Amyloid Precursor Protein Is Required for Normal Function of the Rod and Cone Pathways in the Mouse Retina , 2012, PloS one.
[51] J. Schneider,et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.
[52] I. Lang,et al. Vascular health, diabetes, APOE and dementia: the Aging, Demographics, and Memory Study , 2010, Alzheimer's Research & Therapy.
[53] Alonso Emilio,et al. β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment , 2012, EMBO molecular medicine.
[54] M. Leissring,et al. Identification of BACE2 as an avid ß-amyloid-degrading protease , 2012, Molecular Neurodegeneration.
[55] Mary Sano,et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study , 2008, The Lancet.
[56] G. V. Van Hoesen,et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.
[57] C. Glenn Begley,et al. Raise standards for preclinical cancer research , 2012 .
[58] R. Castellani,et al. Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is ‘too big to fail’ , 2011, The Journal of pathology.
[59] L. Mucke,et al. Amyloid-beta / Fyn – Induced Synaptic , Network , and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer ’ s Disease , 2015 .
[60] S. Prusiner,et al. A Unifying Role for Prions in Neurodegenerative Diseases , 2012, Science.
[61] Jiaquan Xu,et al. Deaths: final data for 2008. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[62] K. Scearce-Levie,et al. A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo , 2011, Science Translational Medicine.
[63] J. Haines,et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.
[64] Katharina Buerger,et al. Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease , 2001, Annals of neurology.
[65] K. Iqbal,et al. Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine. , 2006, FEBS letters.
[66] Juan Manuel Maler,et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer’s disease , 2007, Journal of Molecular Neuroscience.
[67] Henrik Zetterberg,et al. Fluid biomarkers in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[68] R. Tanzi. The genetics of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[69] A. Singleton,et al. TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.
[70] G. Kerchner,et al. Bapineuzumab , 2010, Expert opinion on biological therapy.
[71] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[72] Wendy R. Sanhai,et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.
[73] D. Karussis,et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. , 2006, Archives of neurology.
[74] Martin Ingelsson,et al. The Alzheimer's Disease-Associated Amyloid \(\beta\)-Protein Is an Antimicrobial Peptide , 2010 .
[75] Christian Hölscher,et al. The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease , 2011, The Journal of Neuroscience.
[76] M. Mattson,et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.
[77] L. Mucke,et al. Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.
[78] Asher Mullard. Sting of Alzheimer's failures offset by upcoming prevention trials , 2012, Nature Reviews Drug Discovery.
[79] Holly Soares,et al. Meta-Analysis for Genome-Wide Association Study Identifies Multiple Variants at the BIN1 Locus Associated with Late-Onset Alzheimer's Disease , 2011, PloS one.
[80] Ole A. Andreassen,et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.
[81] N. Hooper,et al. A new take on prions: preventing Alzheimer's disease. , 2008, Trends in biochemical sciences.
[82] V. Papadopoulos,et al. Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity. , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[83] J. Haines,et al. Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .
[84] E. Siemers,et al. Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease , 2009, Expert opinion on pharmacotherapy.
[85] R. Hampson,et al. Development, Optimization and Use of Preclinical Behavioral Models to Maximize the Productivity of Drug Discovery for Alzheimer's Disease , 2008 .
[86] Ayellet V. Segrè,et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height , 2010, Nature.
[87] B. Shukitt-Hale,et al. Copernicus revisited: amyloid beta in Alzheimer’s disease , 2001, Neurobiology of Aging.
[88] F. Hartl,et al. Converging concepts of protein folding in vitro and in vivo , 2009, Nature Structural &Molecular Biology.
[89] Nick C Fox,et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.
[90] J. Trojanowski,et al. The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice , 2012, The Journal of Neuroscience.
[91] D. G. Clark,et al. Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.
[92] Kewei Chen,et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study , 2012, The Lancet Neurology.
[93] M. Wadman. US government sets out Alzheimer’s plan , 2012, Nature.
[94] Greg Miller,et al. Alzheimer's biomarker initiative hits its stride. , 2009, Science.
[95] Jack A. Tuszynski,et al. The Zinc Dyshomeostasis Hypothesis of Alzheimer's Disease , 2012, PloS one.
[96] Clifford R Jack,et al. Testing the Right Target and Right Drug at the Right Stage , 2011, Science Translational Medicine.
[97] L. Buée,et al. MicroRNAs and the Regulation of Tau Metabolism , 2012, International journal of Alzheimer's disease.
[98] David F. Horrobin,et al. Modern biomedical research: an internally self-consistent universe with little contact with medical reality? , 2003, Nature Reviews Drug Discovery.
[99] J. Trojanowski,et al. Total and phosphorylated tau protein as biological markers of Alzheimer’s disease , 2010, Experimental Gerontology.
[100] Z. Stelmasiak,et al. The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis , 2006, Journal of Neural Transmission.
[101] F. Barkhof,et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. , 2012, Archives of neurology.
[102] N. Tabet,et al. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. , 2012, The Cochrane database of systematic reviews.
[103] S. Hirai,et al. Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group , 2002, Neurobiology of Aging.
[104] M. Albert,et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[105] Joan E Bailey-Wilson,et al. Establishing an adjusted p-value threshold to control the family-wide type 1 error in genome wide association studies , 2008, BMC Genomics.
[106] W. Jagust,et al. Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo , 2009, Behavioural neurology.
[107] J. Haines,et al. Genetic susceptibility to Alzheimer disease. , 1995, Trends in genetics : TIG.
[108] M Krawczak,et al. Examination of the current top candidate genes for AD in a genome-wide association study , 2010, Molecular Psychiatry.
[109] Gina N. LaRossa,et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.
[110] Hans Förstl,et al. Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease , 2007, Molecular Psychiatry.
[111] George Perry,et al. Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease? , 2011, Ageing Research Reviews.
[112] O. Arancio,et al. Amyloid-β peptide: Dr. Jekyll or Mr. Hyde? , 2012, Journal of Alzheimer's disease : JAD.
[113] P. Bosco,et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance , 2011, Molecular Psychiatry.
[114] B. Vissel,et al. Tumor Necrosis Factor-Induced Cerebral Insulin Resistance in Alzheimer's Disease Links Numerous Treatment Rationales , 2012, Pharmacological Reviews.
[115] L. Farrer,et al. Power and Pitfalls of the Genome-Wide Association Study Approach to Identify Genes for Alzheimer’s Disease , 2011, Current psychiatry reports.
[116] K. Whaley,et al. Emerging antibody products and Nicotiana manufacturing , 2011, Human vaccines.
[117] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[118] M. Leissring,et al. Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: a role in Alzheimer's disease? , 2012, Journal of Alzheimer's disease : JAD.
[119] Jennifer R. Harris,et al. Combined Genome Scans for Body Stature in 6,602 European Twins: Evidence for Common Caucasian Loci , 2007, PLoS genetics.
[120] Jack A. Tuszynski,et al. Correction: The Zinc Dyshomeostasis Hypothesis of Alzheimer's Disease , 2012, PLoS ONE.
[121] Ottavio Arancio,et al. Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant? , 2012, The Biochemical journal.
[122] E. Mandelkow,et al. Tau protein and tau aggregation inhibitors , 2010, Neuropharmacology.
[123] D. Salmon,et al. The neuropsychological profile of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[124] B. Imbimbo. Why did tarenflurbil fail in Alzheimer's disease? , 2009, Journal of Alzheimer's disease : JAD.
[125] W. Scheper,et al. Endoplasmic reticulum: the unfolded protein response is tangled in neurodegeneration. , 2012, The international journal of biochemistry & cell biology.
[126] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[127] J. Lupski. Structural variation in the human genome. , 2007, The New England journal of medicine.
[128] K. Bales. The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update , 2012, Expert opinion on drug discovery.
[129] R. Mahley,et al. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[130] John P A Ioannidis,et al. Excess significance bias in the literature on brain volume abnormalities. , 2011, Archives of general psychiatry.
[131] Johanna Huttenlocher-Moser. Variant of TREM2 Associated with the Risk of Alzheimer's Disease , 2013 .
[132] David Carling,et al. AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid β-peptide exposure. , 2011, The Biochemical journal.
[133] H. Chui,et al. Impact of Angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. , 2012, Archives of neurology.
[134] S. Gandy. Lifelong management of amyloid-beta metabolism to prevent Alzheimer's disease. , 2012, The New England journal of medicine.
[135] Nick C Fox,et al. Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.
[136] P. Raina,et al. Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline , 2008, Annals of Internal Medicine.
[137] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[138] J. Ioannidis. Extrapolating from Animals to Humans , 2012, Science Translational Medicine.
[139] J. Trojanowski,et al. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. , 2011, Cold Spring Harbor perspectives in medicine.
[140] N. Toni,et al. An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ , 2012, The Journal of Neuroscience.
[141] Nick C Fox. When, where, and how does Alzheimer's disease start? , 2012, The Lancet Neurology.
[142] Frank M LaFerla,et al. Animal models of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[143] J. Lancia,et al. Tau as a therapeutic target in neurodegenerative disease. , 2012, Pharmacology & therapeutics.
[144] M. Matamales,et al. Alzheimer's disease models and functional genomics—How many needles are there in the haystack? , 2012, Front. Physio..
[145] Ming Tong,et al. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.
[146] Ryuichi Morishita,et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes , 2010, Proceedings of the National Academy of Sciences.
[147] Thomas W. Mühleisen,et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.
[148] P. Davies,et al. Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. , 2010, Journal of Alzheimer's disease : JAD.
[149] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.
[150] M. Feany,et al. Tau Promotes Neurodegeneration via DRP1 Mislocalization In Vivo , 2012, Neuron.
[151] M. Farrer,et al. An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[152] F. LaFerla. Preclinical success against Alzheimer's disease with an old drug. , 2012, The New England journal of medicine.
[153] Patrick L. McGeer,et al. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.
[154] A. Muhs,et al. Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors. , 2012, Journal of Alzheimer's disease : JAD.
[155] B. Hyman,et al. The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide , 2010, PloS one.
[156] S. Enna,et al. Defining the role of pharmacology in the emerging world of translational research. , 2009, Advances in pharmacology.
[157] W. Noble,et al. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. , 2009, Trends in molecular medicine.
[158] M. Daly,et al. Variant TREM2 as risk factor for Alzheimer's disease. , 2013, The New England journal of medicine.
[159] M. Folstein,et al. Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis , 2006, Neurobiology of Aging.
[160] G. Marek,et al. Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. , 2011, Biochemical pharmacology.
[161] K. Iqbal,et al. Involvement of in the abnormal hyperphosphorylation of tau and its reversal by Memantine , 2006 .
[162] V. Papadopoulos,et al. Function of β‐amyloid in cholesterol transport: a lead to neurotoxicity , 2002 .
[163] J. Schneider,et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. , 2012, The Journal of clinical investigation.
[164] Liana G. Apostolova,et al. Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative , 2013, Neurobiology of Aging.
[165] Donald A. Wilson,et al. ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models , 2012, Science.
[166] P. Lewczuk,et al. CSF amyloid-b-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia , 2006 .
[167] D. Holtzman,et al. Mapping the Road Forward in Alzheimer’s Disease , 2011, Science Translational Medicine.
[168] Jennifer Williamson,et al. Rare Variants in APP, PSEN1 and PSEN2 Increase Risk for AD in Late-Onset Alzheimer's Disease Families , 2012, PloS one.
[169] S. Gauthier,et al. Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study) , 2011, Archives of medical science : AMS.
[170] C. Carter. Alzheimer's disease plaques and tangles: Cemeteries of a Pyrrhic victory of the immune defence network against herpes simplex infection at the expense of complement and inflammation-mediated neuronal destruction , 2011, Neurochemistry International.
[171] S. Hendrix,et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial , 2008, The Lancet Neurology.
[172] A. Fagan,et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.
[173] Reham M. Abdel-Kader,et al. Mitochondrial Dysfunction—A Pharmacological Target in Alzheimer's Disease , 2012, Molecular Neurobiology.
[174] R. Naviaux. Oxidative Shielding or Oxidative Stress? , 2012, Journal of Pharmacology and Experimental Therapeutics.
[175] Michael Williams,et al. Mitochondrial Function and Dysfunction: An Update , 2012, Journal of Pharmacology and Experimental Therapeutics.
[176] Robert B Wallace,et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.
[177] J. Stamatoyannopoulos. What does our genome encode? , 2012, Genome research.
[178] T. Crow,et al. Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy. , 1994, Molecular neurobiology.
[179] Sonny Dandona,et al. Insulin suppresses the expression of amyloid precursor protein, presenilins, and glycogen synthase kinase-3beta in peripheral blood mononuclear cells. , 2011, The Journal of clinical endocrinology and metabolism.
[180] R. Bartus,et al. The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.
[181] V. Marchesi. Alzheimer's disease 2012: the great amyloid gamble. , 2012, The American journal of pathology.
[182] O. Forlenza,et al. Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature , 2008, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[183] J. Trojanowski,et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.
[184] C. Holmes,et al. Systemic and Central Immunity in Alzheimer's Disease: Therapeutic Implications , 2012, CNS neuroscience & therapeutics.
[185] D. Galasko,et al. Safety, Tolerability, Pharmacokinetics, and Aβ Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals , 2007, Alzheimer disease and associated disorders.
[186] J. Cummings. What Can Be Inferred from the Interruption of the Semagacestat Trial for Treatment of Alzheimer's Disease? , 2010, Biological Psychiatry.
[187] Andrew P Morris,et al. Basic statistical analysis in genetic case-control studies , 2011, Nature Protocols.
[188] D. Quartermain,et al. Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model , 2010, The Journal of Neuroscience.
[189] R. Castellani,et al. Alzheimer disease. , 2010, Disease-a-month : DM.
[190] J. Morris,et al. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease , 2001, Journal of Molecular Neuroscience.
[191] T. Ohm,et al. Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology , 2004, Neurobiology of Aging.
[192] Michael P. Mazanetz,et al. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases , 2007, Nature Reviews Drug Discovery.
[193] C. Beaudry,et al. High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation , 2010, BMC Genomics.
[194] C. Sutherland,et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling , 2010, Proceedings of the National Academy of Sciences.
[195] K. Mullane,et al. Translational semantics and infrastructure: another search for the emperor's new clothes? , 2012, Drug discovery today.
[196] T. Iwatsubo,et al. Aβ Immunotherapy: Intracerebral Sequestration of Aβ by an Anti-Aβ Monoclonal Antibody 266 with High Affinity to Soluble Aβ , 2009, The Journal of Neuroscience.
[197] C. Morissette,et al. Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis , 2007, Neurobiology of Aging.
[198] R. Mahley,et al. Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology. , 2012, Journal of medicinal chemistry.
[199] S. Bornstein,et al. Linking Alzheimer's disease to insulin resistance: the FoxO response to oxidative stress , 2010, Molecular Psychiatry.
[200] Margaret A. Pericak-Vance,et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease , 1997 .
[201] Nick C Fox,et al. Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .
[202] Karl Herholz,et al. Cerebral glucose metabolism in preclinical and prodromal Alzheimer’s disease , 2010, Expert review of neurotherapeutics.
[203] C. Rapezzi,et al. Amyloidosis. Also a heart disease , 2011 .
[204] Jeffrey A. James,et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.
[205] K. Blennow,et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke , 2001, Neuroscience Letters.
[206] Julian D. Gillmore,et al. Chapter 21 Amyloidosis , 2008 .
[207] L. Schneider,et al. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[208] A. Goate,et al. Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort , 2012, Alzheimer's Research & Therapy.
[209] Hui Zheng,et al. Physiological functions of APP family proteins. , 2012, Cold Spring Harbor perspectives in medicine.
[210] Pritam Das,et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. , 2003, The Journal of clinical investigation.
[211] Hyman Gross,et al. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration , 2007, Journal of Neuroinflammation.
[212] T. Hartmann,et al. Amyloid beta as a regulator of lipid homeostasis. , 2007, Trends in molecular medicine.
[213] M. D. Lindner. Clinical attrition due to biased preclinical assessments of potential efficacy. , 2007, Pharmacology & therapeutics.
[214] Katharina Buerger,et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. , 2004, Archives of general psychiatry.
[215] P. Elliott,et al. Sirtuins — novel therapeutic targets to treat age-associated diseases , 2008, Nature Reviews Drug Discovery.
[216] V. Hillier,et al. HEAD INJURY AND THE RISK OF ALZHEIMER'S DISEASE: A CASE CONTROL STUDY , 1997, International journal of geriatric psychiatry.
[217] S. Love,et al. Neprilysin and Insulin-Degrading Enzyme Levels Are Increased in Alzheimer Disease in Relation to Disease Severity , 2009, Journal of neuropathology and experimental neurology.
[218] G. Schellenberg,et al. Head injury and risk of Alzheimer's disease by apolipoprotein E genotype. , 1997, American journal of epidemiology.
[219] Seth Love,et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.
[220] R. McShane,et al. Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review , 2012, BMJ Open.
[221] B. Winblad,et al. Alzheimer's disease: clinical trials and drug development , 2010, The Lancet Neurology.
[222] D. Triggle. Nous sommes tous des bacteries: implications for medicine, pharmacology and public health. , 2012, Biochemical pharmacology.
[223] Hyoung-Gon Lee,et al. Tau phosphorylation in Alzheimer's disease: pathogen or protector? , 2005, Trends in molecular medicine.
[224] Hyoung-Gon Lee,et al. Alzheimer Disease Pathology As a Host Response , 2008, Journal of neuropathology and experimental neurology.
[225] C. Begley,et al. Drug development: Raise standards for preclinical cancer research , 2012, Nature.
[226] Nick C Fox,et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.
[227] L. Buée,et al. Association between IgM Anti-Herpes Simplex Virus and Plasma Amyloid-Beta Levels , 2011, PloS one.
[228] Xinsheng Yao,et al. Epidermal growth factor receptor is a preferred target for treating Amyloid-β–induced memory loss , 2012, Proceedings of the National Academy of Sciences.
[229] Anders Wallin,et al. Amino-Truncated β-Amyloid42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment , 2005 .
[230] H. Neumann,et al. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2 , 2005, The Journal of experimental medicine.
[231] Nick C Fox,et al. Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.
[232] I. Grundke‐Iqbal,et al. Mechanisms of tau-induced neurodegeneration , 2009, Acta Neuropathologica.
[233] Donna M. Martin,et al. Phenotypic heterogeneity of genomic disorders and rare copy-number variants. , 2012, The New England journal of medicine.
[234] S. Lipton,et al. Aβ neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-d-aspartate receptors , 2012, Proceedings of the National Academy of Sciences.
[235] B. Fischer,et al. Abeta40, either soluble or aggregated, is a remarkably potent antioxidant in cell-free oxidative systems. , 2009, Biochemistry.
[236] E. Siemers,et al. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease , 2012, Alzheimer's & Dementia.
[237] S. Hull,et al. The ethics of early evidence--preparing for a possible breakthrough in Alzheimer's disease. , 2012, The New England journal of medicine.
[238] B. Winblad,et al. Insulin levels are decreased in the cerebrospinal fluid of women with prodomal Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.
[239] G. Perry,et al. Do neurons have a choice in death? , 2001, The American journal of pathology.
[240] C. Broeckhoven. The future of genetic research on neurodegeneration , 2010, Nature Medicine.
[241] R. Motter,et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.
[242] M. Weiner,et al. Genomic Copy Number Analysis in Alzheimer's Disease and Mild Cognitive Impairment: An ADNI Study , 2011, International journal of Alzheimer's disease.
[243] A. Fagan,et al. Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta , 2009, neurogenetics.
[244] D. Selkoe,et al. Resolving controversies on the path to Alzheimer's therapeutics , 2011, Nature Medicine.
[245] T. Montine,et al. Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial , 2011 .
[246] K. Blennow,et al. Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease , 2010, Alzheimer's Research & Therapy.
[247] J. Trojanowski,et al. Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.